Go to the list of all blogs
AI dvisor's Avatar
published in Blogs
Nov 19, 2026
TickeronGET DAILY SIGNALS
VEEV vs PHR: Weighing Veeva Systems Against Phreesia in Healthcare Technology

VEEV vs PHR: Weighing Veeva Systems Against Phreesia in Healthcare Technology

Key Takeaways

  • Veeva Systems (VEEV) is a large-cap, profitable life sciences software leader, while Phreesia (PHR) is a smaller healthcare engagement and payments platform only recently reaching sustained profitability.
  • Recent relative performance has diverged sharply: VEEV has rallied strongly on AI product momentum, while PHR has been pressured by reduced revenue visibility in its Network Solutions segment.
  • VEEV is raising full-year guidance, whereas PHR lowered its fiscal 2027 revenue outlook earlier in the year, reshaping sentiment across both names.
  • Tickeron AI Verdict: Based on trend consistency, profitability, and catalysts, Tickeron's AI would currently favor VEEV over PHR.
  • For more detail, explore PHR Major News, PHR Today's Price Move, VEEV Major News, and VEEV Today's Price Move.

Setting the Context

Investors and traders evaluating the healthcare technology space often weigh high-growth, earlier-stage disruptors against established, profitable software franchises. This stock comparison examines PHR, the parent of Phreesia, a patient activation and payment platform, against VEEV, Veeva Systems, a cloud software leader serving the life sciences industry. The two companies operate in adjacent corners of healthcare technology but differ meaningfully in scale, business model, and market positioning. For growth-oriented traders assessing relative performance and momentum, and for longer-term investors comparing financial durability, understanding these contrasts helps clarify which name currently offers more consistent trend characteristics in the market. I also checked this using Tickeron’s AI Screener to see how the stocks compare within the broader industry.

PHR Overview and Recent Performance

Phreesia (PHR) provides an integrated software-as-a-service (SaaS) platform and payment solutions that help healthcare organizations manage patient intake, outreach, and billing. The company has scaled to support a significant share of U.S. ambulatory patient visits and has diversified into network solutions serving pharmaceutical marketers.

Recent market activity has been mixed. The company has reported several consecutive quarters of profitability, with rising adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization), improving operating cash flow, and debt reduction. However, sentiment has been pressured by reduced visibility into pharmaceutical marketing commitments within its Network Solutions segment. Earlier in the year, management lowered its fiscal 2027 revenue outlook, and the shares experienced a sharp sell-off in response. In recent weeks, the stock has traded within a comparatively narrow range, reflecting ongoing debate between improving margins and slower top-line growth, while several analyst firms have trimmed targets or adopted a more cautious stance.

VEEV Overview and Recent Performance

Veeva Systems (VEEV) delivers cloud software, data, and consulting solutions to the global life sciences industry. Its two core franchises are Veeva Vault, a content and data management platform, and Vault CRM, a customer relationship management (CRM) suite that has been winning large enterprise deployments from major pharmaceutical clients.

Recent performance has been notably strong. The company has posted double-digit revenue growth, expanded operating margins, and raised its full-year guidance on the back of robust subscription demand. A steady cadence of product announcements centered on artificial intelligence—including agentic tools for clinical data configuration and safety-case triage—has reinforced investor enthusiasm. In recent weeks, the stock has traded near the upper end of its range after a substantial multi-month advance, though it has shown some near-term volatility amid broader sector swings. Analysts have generally maintained favorable ratings, citing resilient execution and AI-driven upside. From what I see, the AI momentum here aligns well with broader sector trends.

Head-to-Head Comparison

The two companies diverge across several dimensions. VEEV operates a large-scale, highly profitable subscription model serving life sciences enterprises, with a multi-billion-dollar cash position and a market capitalization in the tens of billions. PHR, by contrast, is a smaller company whose revenue spans subscriptions, payment processing, and network solutions tied to healthcare providers and pharmaceutical marketers.

Growth drivers also differ. VEEV benefits from durable CRM share gains and a broadening AI product cycle, which has supported margin expansion and guidance increases. PHR has demonstrated improving profitability and cash flow but faces greater uncertainty around revenue growth, particularly within its pharmaceutical-facing network solutions business. Risk profiles reflect this gap: VEEV carries execution and competitive risks but relatively stable demand visibility, while PHR contends with forecasting variability and has drawn shareholder litigation related to its revised guidance. In terms of momentum, VEEV has shown stronger recent trend consistency, whereas PHR has remained range-bound as the market weighs margin gains against slower growth.

Tickeron AI Verdict

On the basis of observable factors, Tickeron's AI would currently favor VEEV over PHR. Veeva Systems combines consistent positive trend structure, rising guidance, expanding margins, and a pipeline of identifiable AI-related catalysts. These characteristics generally align more closely with the stability and relative strength signals that momentum-oriented models prioritize. Phreesia's improving profitability is a genuine positive, but reduced revenue visibility and a more fragmented analyst outlook introduce greater uncertainty into its near-term trend. This assessment is probabilistic rather than definitive, reflecting the current balance of trend, catalysts, and market positioning across the two names.

Exploring Automated Trading Strategies

In my analysis, I often turn to Tickeron’s AI Trading Bots to test how different automated approaches might align with names like these. The platform offers a range of bots with varying styles, timeframes, and performance records across thousands of tickers. Reviewing the curated selections helps identify strategies that fit current market conditions, whether for short-term momentum or longer-term trends. This adds another layer to evaluating relative strength between stocks.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: VEEV, PHR

VEEV sees MACD Histogram crosses below signal line

VEEV saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 28, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 50 instances where the indicator turned negative. In 35 of the 50 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 70%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VEEV as a result. In 52 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.

VEEV moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VEEV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.

The Aroon Indicator for VEEV entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +0.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where VEEV advanced for three days, in 179 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.

VEEV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. VEEV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.617) is normal, around the industry mean (4.523). VEEV has a moderately high P/E Ratio (48.989) as compared to the industry average of (12.601). Projected Growth (PEG Ratio) (1.248) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (12.739) is also within normal values, averaging (6.105).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VEEV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 3.31B. The market cap for tickers in the group ranges from 708 to 49.18B. VEEV holds the highest valuation in this group at 49.18B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was 5%. PRVA experienced the highest price growth at 4%, while BFRG experienced the biggest fall at -29%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was 27%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -13%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 53
Price Growth Rating: 56
SMR Rating: 86
Profit Risk Rating: 97
Seasonality Score: 0 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of industry-specific, cloud-based software solutions for the life sciences industry

Industry ServicestotheHealthIndustry

Industry
Packaged Software
Address
4280 Hacienda Drive
Phone
+1 925 452-6500
Employees
7928
Web
https://www.veeva.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.